Renoprotective Effects of Telbivudine in Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 1, 2013

Primary Completion Date

June 16, 2016

Study Completion Date

May 31, 2018

Conditions
Hepatitis B, ChronicChronic Kidney Diseases
Interventions
DRUG

Telbivudine

CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.

Trial Locations (1)

Unknown

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT03778567 - Renoprotective Effects of Telbivudine in Chronic Hepatitis B | Biotech Hunter | Biotech Hunter